Amwell (American Well)

Amwell reported Q2 2026 revenue of $52.0 million, at the top end of guidance, with subscription revenue reaching $25.7 million and Amwell Medical Group visit revenue at $24.4 million. Gross margin was 53%. Net loss was ($9.6) million, improving from ($10.3) million in Q1 2026. Adjusted EBITDA was ($1.2) million versus ($3.1) million in Q1. Platform visits totaled 0.8 million. The company raised its full-year 2026 revenue outlook to $200–$205 million (from $195–$205 million) and improved adjusted EBITDA guidance to ($9)–($7) million (from ($16)–($12) million). Q3 2026 guidance calls for $46–$48 million revenue and ($5)–($3) million adjusted EBITDA. Management reiterated a target of positive operating cash flow in Q4 2026.

No articles ingested yet for Amwell (American Well). Once the hourly news pipeline is live, every article the classifier tags as mentioning this company appears here with its one-line AI summary and sentiment.